As a control, we used two lung cancer-derived cell lines, A549 (homozygous KRAS G12S mutation; KRAS non-addicted) and H358 (heterozygous KRAS G12C mutation; KRAS-addicted) [16], and melanoma-derived cell line, A375 (homozygous BRAF V600E mutation; BRAF-addicted) [19]. This evidence concerns the gene KRAS and lung carcinoma.